Impaired glucose tolerance and dyslipidaemia as late effects after bone-marrow transplantation in childhood

被引:208
作者
Taskinen, M
Saarinen-Pihkala, UM
Hovi, L
Lipsanen-Nyman, M
机构
[1] Univ Helsinki, Hosp Children & Adolescents, FIN-00290 Helsinki, Finland
[2] Univ Kuopio, Childrens Hosp, FIN-70211 Kuopio, Finland
关键词
D O I
10.1016/S0140-6736(00)02717-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background This follow-up study aimed to assess the frequency of late effects on glucose and lipid metabolism after bone-marrow transplantation in childhood. Methods 23 long-term survivors (median age 20 years) were studied 3-18 years after bone-marrow transplantation and compared with 23 healthy controls matched for age and sex and with 13 patients in remission from leukaemia. Findings 12 (52%) of the 23 bone-marrow transplantation patients had insulin resistance, including impaired glucose tolerance in six and type 2 diabetes in four. The core signs of the metabolic syndrome (hyperinsulinaemia and hypertriglyceridaemia combined), were found in nine (39%) of the bone-marrow transplantation patients compared with one (8%) of the 13 leukaemia patients and none of the healthy controls (p=0.0015). The frequency of insulin resistance increased with the time since bone-marrow transplantation. Abdominal obesity, but not overweight, was common among the patients with insulin resistance. Interpretation Long-term survivors of bone-marrow transplantation are at substantial risk of insulin resistance, impaired glucose tolerance, and type 2 diabetes even at normal weight and young age. They also develop typical signs of the metabolic syndrome. We advocate measurement of serum lipids, fasting blood glucose, and serum insulin for the follow-up of all patients who undergo transplants in childhood, to be continued regularly and possibly lifelong.
引用
收藏
页码:993 / 997
页数:5
相关论文
共 24 条
[1]   Accelerated atherosclerosis in a patient with post-BMT nephropathy [J].
Akasheh, M ;
Priyanath, A ;
Pello, N ;
Watry, P ;
Vesole, D .
BONE MARROW TRANSPLANTATION, 1999, 23 (02) :199-199
[2]  
*AM DIAB ASS, 1996, DIABETES CARE S1, V19, pS4
[3]   Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment [J].
Cutfield, WS ;
Wilton, P ;
Bennmarker, H ;
Albertsson-Wikland, K ;
Chatelain, P ;
Ranke, MB ;
Price, DA .
LANCET, 2000, 355 (9204) :610-613
[4]  
FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
[5]   Leptin:: physiology and pathophysiology [J].
Frühbeck, G ;
Jebb, SA ;
Prentice, AM .
CLINICAL PHYSIOLOGY, 1998, 18 (05) :399-419
[6]  
Gavin JR, 1997, DIABETES CARE, V20, P1183
[7]   A prospective analysis of the HOMA model - The Mexico City Diabetes Study [J].
Haffner, SM ;
Gonzalez, C ;
Miettinen, H ;
Kennedy, E ;
Stern, MP .
DIABETES CARE, 1996, 19 (10) :1138-1141
[8]  
HOVI L, 1990, BONE MARROW TRANSPL, V5, P183
[9]  
Kahn R, 1998, DIABETES CARE, V21, P310
[10]   QUANTITATION OF MUSCLES AND FAT BY ULTRASONOGRAPHY - A USEFUL METHOD IN THE ASSESSMENT OF MALNUTRITION IN CHILDREN [J].
KOSKELO, EK ;
KIVISAARI, LM ;
SAARINEN, UM ;
SIIMES, MA .
ACTA PAEDIATRICA SCANDINAVICA, 1991, 80 (6-7) :682-687